James Edward Bass is Director at REATA PHARMACEUTICALS INC (RETA). They have made 8 open-market trades across 1 company since 2016, most recently 2019-03-05.
CIK 0001358762
7 open-market purchases totalling $1.3M since 2016, against 1 sale. Across 7 scored buys the stock is up 22.7% at ninety days, and 17.8 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| RETA | 11,703 | $2.0M |
Shares reported on the most recent Form 4, priced at the 2019-03-07 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 71% | 86% | 71% |
| Avg Move | +8.4% | +9.8% | +22.7% |
| Alpha | +7.2% | +8.4% | +17.8% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RETA | SELL | 2019-03-05 | 2019-03-07 | $100.29 | $1.2M | +3.3% | -2.0% | -2.3% |
| RETA | BUY | 2018-12-20 | 2018-12-21 | $52.12 | $46K | +16.9% | +48.6% | +85.4% |
| RETA | BUY | 2018-11-16 | 2018-11-19 | $59.33 | $199K | +6.9% | -7.3% | +46.1% |
| RETA | BUY | 2018-07-25 | 2018-07-26 | $78.34 | $139K | -1.4% | +2.6% | -24.1% |
| RETA | BUY | 2017-11-15 | 2017-11-16 | $24.02 | $187K | +6.1% | +11.2% | +10.0% |
| RETA | BUY | 2017-08-01 | 2017-08-01 | $31.00 | $250K | -6.8% | +1.2% | -1.6% |
| RETA | BUY | 2016-12-14 | 2016-12-15 | $21.76 | $218K | +0.2% | +0.2% | +23.4% |
| RETA | BUY | 2016-06-01 | 2016-06-02 | $11.50 | $264K | +37.2% | +12.0% | +20.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.